Dynavax Technologies | DVAX - Cash And Equivalent


Dynavax Technologies reported $160.25M in Cash and Equivalent for its fiscal quarter ending in September of 2025.



Cash And Equivalent Change Date
AbbVie USD 5.23B 400M Dec/2025
Adma Biologics USD 87.63M 26.24M Dec/2025
Agenus USD 3.46M 6.08M Sep/2025
Amgen USD 9.13B 316M Dec/2025
AstraZeneca USD 8.14B 1.08B Sep/2025
Biogen USD 3.01B 854.3M Dec/2025
BioMarin Pharmaceutical USD 1.31B 61.57M Dec/2025
Bristol-Myers Squibb USD 10.21B 5.52B Dec/2025
Gilead Sciences USD 7.33B 2.19B Sep/2025
Glaxosmithkline GBP 3.3B 303M Sep/2025
Merck USD 18.17B 10.16B Sep/2025
Minerva Neurosciences USD 82.3M 70.02M Dec/2025
Nektar Therapeutics USD 15.12M 25.92M Dec/2025
Neurocrine Biosciences USD 713M 372.8M Dec/2025
Novartis USD 9.56B 2.9B Sep/2025
Pfizer USD 1.34B 295M Sep/2025
Regeneron Pharmaceuticals USD 18.87B 16.36B Dec/2025
Roche Holding CHF 7.55B 579M Jun/2025
Sarepta Therapeutics USD 801.28M 188.2M Dec/2025
TG Therapeutics USD 199.51M 21.2M Dec/2025
Vertex Pharmaceuticals USD 6.61B 321.1M Dec/2025